Open Clinical Investigation to Evaluate Efficacy and Safety of the Medical Device "Sterimar Stop & Protect Irritation & Dryness" in Adults With Dry or Irritated Nose

The goal of this clinical trial is to test symptom relief in subjects suffering from irritated or dry nasal passages. The main question it aims to answer is whether use of the nasal spray provides relief from dry nose symptoms. Participants will use the product for one week and report on the severity of their symptoms before and during use.

Start Date27 Oct 2023

Sponsor / Collaborator

Church & Dwight Co., Inc.

100 Clinical Results associated with Church & Dwight Co., Inc.

0 Patents (Medical) associated with Church & Dwight Co., Inc.

Literatures (Medical) associated with Church & Dwight Co., Inc.

01 May 2024·Poultry Science

Organ growth and fermentation profiles of broilers differing in body growth rate

Article

Author: Mackie, Roderick I ; Smith, Alexandra H ; Dilger, Ryan N ; Jespersen, Julianna C ; Cao, Chang ; Oelschlager, Maci L ; Gorenz, Brad

This study sought to determine the relationship among broiler performance, organ development, and indicators of microbiota colonization. A total of 1,200 two-day-old male Ross 308 broiler chicks, divided among 3 cohorts of equal size, were housed in battery cages, and allotted based on body weight. On study d 11, birds were weighed, and birds with BW gain within the 10th and 90th percentiles were assigned to the Slow and Fast groups, respectively. Birds (n = 30 for each group) selected on d 11 were provided water and a corn-soybean meal-based diet ad libitum while maintained individually through study d 25 (i.e., a 14-d growth period). Parameters regarding growth performance, organ and intestine weights and lengths, and intestinal volatile fatty acid concentrations were measured. All data were analyzed by one-way ANOVA using the Mixed procedure of SAS. Fast birds exhibited greater (P < 0.001) BW gain and feed intake than slow birds, but feed conversion ratio (FCR) did not differ (P = 0.19). Additionally, Slow birds had higher (P < 0.05) relative weights (% of BW) for nearly all organs on d 11 and 25, most notably the gizzard, proventriculus, pancreas, and liver. Conversely, intestinal sections were longer (P < 0.05) in the Fast birds. Measurement of gut histomorphology did not show any notable differences between growth rate groups in terms of villi height, crypt depth, or their ratio for either time-point (P > 0.05). In terms of volatile fatty acid concentrations of luminal contents, acetate concentrations were 10.2% higher (P < 0.001) in the ileum of the Slow birds compared with Fast birds on d 25. Overall, the findings suggest that total BW gain is influenced by the development of metabolically active organs, as supported by lower weight gain in Slow birds with relatively larger organ weights and shorter intestinal lengths than their Fast counterparts. The general lack of differences in fermentation end-product concentrations in luminal contents does not rule out influence of the microbiota on growth rate of broilers, which warrants further investigation.

28 Oct 2023·Journal of Animal Science

110 Effects of Supplementation of Refined Functional Carbohydrates in Sow and Piglet Diets on Performance During pre-Weaning and in Nursery in Pigs Fed Diets without any Antimicrobials

Author: Vargas, Antonio ; Jalukar, Sangita ; Carrion-Lopez, Maria-Jose

AbstractThe objective of the study was to test effects of supplementation of Refined Functional Carbohydrates in sow and piglet diets on performance during pre-weaning and in nursery in pigs fed diet without antibiotics and pharmacological level of Zinc Oxide. Hybrid-hyper prolific sows (n = 269) and their litters [(Landrace x Large-white) x Pietrain] were used for the trial. All sows participated in the gestation phase, but only 94 of them were monitored throughout the lactation phase and their piglets during nursery phase. During the first 90 days of gestation all sows were fed a common standard diet. On approximately d 90 of gestation, sows were randomly assigned to one of the following treatments: 1) control group (CONTROL, n = 134), and 2) RFC group (0.02% CELMANAX SCP, n = 135), until transfer to farrowing unit (d 110 of gestation). A subset of sows received the corresponding lactation feed (CONTROL n = 54 and 0.02% CELMANAX SCP, n =4 6) after entering the farrowing room and throughout lactation. The day after farrowing, piglets were weighed individually and the number of piglets born alive, stillborn, and mummified were recorded. The piglets were supplemented with creep feed from day 7 of lactation with identical treatments as their sows. Sow body condition and feed intake during lactation and rectal temperature post farrowing were recorded. Piglet BW at weaning, pre-weaning mortality and medical treatments were recorded. Fecal score of sows and litter during pre-weaning were also recorded. At weaning, piglets were assigned to the 2 treatments (CONTROL and CELMANAX SCP, 0.02%), according to lactation treatment with 30 piglets/pen and 22 pens/treatment. Treatments were fed in the first two phases of nursery, 0-7 days and 7-21 days post weaning. Nursery pig performance was recorded. Data were analyzed with statistic software Minitab version 17.0 Windows using sow as the experimental unit for variables of gestation and lactation stages, and pen for the variables during nursery period. Sows that received diets supplemented with RFC showed a reduced mortality rate of piglets at 24 h of life (P=0.05). At weaning, an increase in piglet BW (P< 0.05) and a trend for greater ADG (P = 0.07) was noted in piglets from RFC supplemented multiparous sows. Nursery pigs fed diets supplemented with RFC had greater BW (P=0.03) and ADG (P=0.03) and a trend for greater ADFI during the first 21 days of nursery (P=0.08). In conclusion, sows supplemented with RFC in late gestation diet (d 90 to d 110) had reduced piglet mortality 24 h postpartum. Continued supplementation of RFC in lactation diet of sows and in piglet creep increased piglet weaning weight. Piglets supplemented with RFC in the early nursery stage (0 to 21d) also saw an improvement in the main productive indicators.

01 Sep 2023·Journal of Indian Society of Periodontology

Effectiveness of subgingival irrigation and powered toothbrush as home care maintenance protocol in type 2 diabetic patients with active periodontal disease: A 4-month randomized controlled trial

Article

Author: Jain, Ashish ; Gupta, Jyoti ; Grover, Vishakha ; Kapur, Vinay ; Kaur, Jaspreet ; Samujh, Tanvi ; Lyle, Deborah M. ; Gupta, Mili ; Mehta, Manjula

Background:There is a bidirectional link between diabetes and periodontal disease. Control of active periodontal infection is an essential requisite to maintain optimal oral and systemic health in diabetic patients. The purpose of this study was to evaluate the efficacy of subgingival irrigation and powered toothbrush as home care maintenance protocol in type 2 diabetic patients with active periodontal disease compared to routine oral hygiene.Materials and Methods:Forty (n = 40) diabetic (HbA1c >7%) patients were enrolled in this parallel, examiner-blind, interventional clinical trial. Patients were randomized into two groups: Group A (sonic toothbrush and irrigation with water twice daily) or Group B (manual toothbrush and mouth rinsing with 0.12% Chlorhexidine gluconate (CHX) twice daily)). All patients received Phase I therapybefore the start of the study. Clinical parameters (plaque index [PI], gingival index [GI], oral hygiene index [OHI], pocket depth [PD], clinical attachment level [CAL], and bleeding index [BI]) were assessed at baseline, 1, 2, and 4 months. Levels of C-reactive protein (CRP), HbA1c, and interleukin (IL)-1 β were assessed at baseline and 4 months only. Verbal and written instructions were provided to each subject specific to their intervention allocation. Descriptive, parametric, and nonparametric analyses were used where appropriate.Results:Sixteen (n = 16) patients in Group A and fifteen (n = 15) patients in Group B completed the 4-month study. Both groups showed a significant difference in BI, PD, CAL, and HbA1c from baseline to 4 months. There were no differences within groups for OHI, GI, or PI and CRP, IL-1 β. The results are based on an underpowered study due to the drop out of 9 patients reducing the number below the needed 19 patients per group based on the power analysis.Conclusion:Results from this study provide information for future studies on self-care regimens for individuals living with Type 2 diabetes.

News (Medical) associated with Church & Dwight Co., Inc.

27 Sep 2024

·www.prnewswire.com

Introducing Waterpik™ Sensonic™ Complete Care: The Ultimate Powerhouse for Your Personalized Oral Care

WATERPIK SENSONIC Complete Care combines the #1 recommended water flosser brand by dental professionals1 with the award winning SENSONIC Toothbrush in one compact device! FORT COLLINS, Colo., Sept. 27, 2024 /PRNewswire/ -- WATERPIK™, the #1 selling water flosser brand in the U.S., announces the launch of their new SENSONIC Complete Care and its acceptance by the American Dental Association, which is recognized by dental professionals as the gold standard for evaluating safety and effectiveness of oral care products. SENSONIC Complete Care delivers a transformative clean so you can take control of your oral health. WATERPIK SENSONIC Complete Care WATERPIK water flosser specialty tips, 360-degree tip rotation, and ten (10) water pressure settings WATERPIK SENSONIC toothbrush WATERPIK SENSONIC Complete Care The brand's latest innovation includes the SENSONIC Toothbrush that cleans deep in hard-to-reach areas with contoured bristles that hug tooth surfaces plus three (3) cleaning modes: clean, stain removal, and gum care. Alongside the SENSONIC Toothbrush, the WATERPIK water flosser comes with five (5) specialty flossing tips, 360-degree tip rotation to reach the whole mouth, and ten (10) water pressure settings, delivering a truly customizable experience. The five (5) flossing tips include: two (2) Precision Tips for general use, one (1) Orthodontic Tip for braces and orthodontics, one (1) Plaque Seeker Tip for crowns and bridges, and one (1) Implant Denture Tip for implant retained dentures. Each tip is specially designed to address the most common dental needs. "WATERPIK'S latest innovation is a true testament to the brand's commitment to developing personalized oral care solutions that allow consumers to truly take control of their oral health," said Charisse Winecki, WATERPIK Vice President of Global Marketing. "Harnessing the power of water, SENSONIC Complete Care combines two of the brand's fan-favorite products into one device, making it easy to improve oral health at home." SENSONIC Complete Care transforms the power of water with PRECISIONPULSE™ technology, proven to deliver an effective combination of water pressure and pulsations removing up to 99.9% of plaque bacteria2 that can cause gingivitis, cavities, and bad breath. When the WATERPIK water flosser and SENSONIC Toothbrush are used together as directed, SENSONIC Complete Care is up to 3X as effective as manual brushing for improving gum health. The new WATERPIK SENSONIC Complete Care is now available for purchase at Amazon and Walmart.com. For more information, visit waterpik.com. About The Waterpik™ Brand WATERPIK is the #1 water flosser brand recommended by dental professionals in the U.S.1 and are proudly engineered in Colorado, USA. The company, founded in 1962 by a dentist and hydraulic engineer, has a rich history of innovation and design, engineering their products to deliver the wellness benefits of water in multiple new-to-the world products – including the iconic original WATER FLOSSER and the world's first flossing toothbrush – SONIC FUSION™. Water Pik, Inc. is a wholly-owned subsidiary of Church & Dwight Co., Inc. 1 Professional AAU, 400 Dental Professionals, October 2023. 2 From treated areas. In vitro, data on file. Media contact: [email protected] SOURCE Waterpik® WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

30 Mar 2023

·www.businesswire.com

Church & Dwight to Webcast Discussion of First Quarter 2023 Results on April 27

EWING, N.J.--( BUSINESS WIRE )--Church & Dwight Co., Inc. (NYSE: CHD) will host a conference call to discuss first quarter 2023 earnings results on April 27, 2023, at 10:00 a.m. ET. Media and investors may access the live audio webcast at www.churchdwight.com beginning at 10:00 a.m. ET. The webcast will also be available for replay. Church & Dwight Co., Inc., founded in 1846, is the leading U.S. producer of sodium bicarbonate, popularly known as baking soda. The Company manufactures and markets a wide range of personal care, household, and specialty products under recognized brand names such as ARM & HAMMER®, TROJAN®, OXICLEAN®, SPINBRUSH®, FIRST RESPONSE®, NAIR®, ORAJEL®, XTRA®, L’IL CRITTERS® and VITAFUSION®, BATISTE®, WATERPIK®, ZICAM®, THERABREATH®, and HERO MIGHTY PATCH®. These 14 key brands represent approximately 85% of the Company’s product sales. For more information, visit the Company’s website.

Financial Statement

26 Aug 2022

·www.prnewswire.com

Fertility Testing Devices Market: 40% of Growth to Originate from North America, Ovulation Predictor Kits Segment to be Significant for Revenue Generation - Technavio

NEW YORK, Aug. 26, 2022 /PRNewswire/ -- The " Fertility Testing Devices Market Forecast and Analysis 2022-2026" report has been added to Technavio's offering. With ISO 9001:2015 certification, Technavio is proudly partnering with more than 100 Fortune 500 companies for over 16 years. The fertility testing devices market share is expected to increase to USD 153.91 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.73%. Technavio categorizes the global fertility testing devices market as a part of the global healthcare equipment market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the fertility testing devices market during the forecast period. Attractive Opportunities in Fertility Testing Devices Market by Product and Geography - Forecast and Analysis 2022-2026 To know more about the parent market analysis - Request a FREE Sample Now! Fertility Testing Devices Market: Segmentation Analysis The fertility testing devices market report is segmented by Product (Ovulation predictor kits, Fertility monitors, and Male fertility testing devices) and Geography (North America, Europe, Asia, and the Rest of the World (ROW)). Revenue Generating Segment : The fertility testing devices market share growth in the ovulation predictor kits segment will be significant for revenue generation. The rising median age of first-time pregnancies in women, the increasing preference for ovulation predictor kits due to the convenience they offer, their high efficacy and low-cost benefits, rapid technological advances, and the innovations in the development of such kits are expected to drive the growth of this segment during the forecast period. Regional Highlights : 40% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for fertility testing devices in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions. The rising prevalence of PCOS, the increasing age of first-time pregnancy, and the declining fertility rate in the region will facilitate the fertility testing devices market growth in North America over the forecast period. Grab a sample report for additional insights into the contribution of all the segments & regional opportunities in the report. Fertility Testing Devices Market - Key Market Dynamics Market Driver - The key factor driving growth in the fertility testing devices market is the rising median age of first-time pregnancies in women. In Mexico, the mean age of women at first childbirth was 20-24 years. In Ireland, Italy, South Korea, Spain, and Switzerland, the average age of women at first childbirth was 30-34 years. In Hungary, Latvia, Lithuania, Poland, the Slovak Republic, Turkey, and the US, the average age of women at first childbirth was 25-29 years. Delayed childbearing due to the high prevalence of polycystic ovary syndrome (PCOS), ruptured uterus, amniotic fluid embolism, and delayed parenting are some of the reasons for late pregnancies. Market Challenges - The stringent regulatory bodies will be a major challenge for the fertility testing devices market during the forecast period. Factors such as faulty device designs, malfunction of the devices, and precision and accuracy error rates are some of the issues associated with fertility testing devices, causing misdiagnosis and improper patient management and treatment. Hence, stringent government regulations are imposed on the manufacturing of fertility testing devices. Different regulatory bodies are appointed to guide fertility testing device manufacturers and marketers. Regulatory bodies such as the US Food and Drug Administration (FDA) and the European Union (EU) authorities play a major role in approving these devices and their components. To learn about additional key drivers, trends, and challenges - Request a FREE Sample Report right now! Fertility Testing Devices Market - Vendor Analysis The fertility testing devices market is fragmented and the vendors are deploying growth strategies such as introducing innovative products to compete in the market. Abbott Laboratories AdvaCare Pharma Alfa Scientific Designs Inc Ava AG Babystart Ltd. bioZhena Corp. Church and Dwight Co. Inc. Geratherm Medical AG Get Stix Inc. Medical Electronic Systems LLC Piramal Enterprises Ltd. PREGMATE Prestige Consumer Healthcare Inc. Quanovate Tech Inc. Quidel Corp. Samplytics Technologies Pvt Ltd. Tempdrop Ltd. The Procter and Gamble Co. UEBE Medical GmbH Valley Electronics AG To gain access to more vendor profiles with their key offerings available with Technavio, Click Here The competitive scenario provided in the Fertility Testing Devices Market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.Don't wait, Make a strategic approach & boost your business goals with our Fertility Testing Devices Market Forecast Report - Buy Now! Related Reports: The transcatheter pulmonary valve market share is expected to increase by USD 51.74 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.1%. The ureteroscopy devices market share is expected to increase to USD 210.84 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.3%. Browse for Technavio "Healthcare Market" Research Reports Key Topics Covered: 1 Executive Summary 1.1 Market Overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Product 5.1 Market segments Exhibit 24: Chart on Product - Market share 2021-2026 (%) Exhibit 25: Data Table on Product - Market share 2021-2026 (%) 5.2 Comparison by Product Exhibit 26: Chart on Comparison by Product Exhibit 27: Data Table on Comparison by Product 5.3 Ovulation predictor kits - Market size and forecast 2021-2026 Exhibit 28: Chart on Ovulation predictor kits - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Ovulation predictor kits - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Ovulation predictor kits - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Ovulation predictor kits - Year-over-year growth 2021-2026 (%) 5.4 Fertility monitors - Market size and forecast 2021-2026 Exhibit 32: Chart on Fertility monitors - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Fertility monitors - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Fertility monitors - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Fertility monitors - Year-over-year growth 2021-2026 (%) 5.5 Male fertility testing devices - Market size and forecast 2021-2026 Exhibit 36: Chart on Male fertility testing devices - Market size and forecast 2021-2026 ($ million) Exhibit 37: Data Table on Male fertility testing devices - Market size and forecast 2021-2026 ($ million) Exhibit 38: Chart on Male fertility testing devices - Year-over-year growth 2021-2026 (%) Exhibit 39: Data Table on Male fertility testing devices - Year-over-year growth 2021-2026 (%) 5.6 Market opportunity by Product Exhibit 40: Market opportunity by Product ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 42: Chart on Market share by geography 2021-2026 (%) Exhibit 43: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 44: Chart on Geographic comparison Exhibit 45: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Germany - Market size and forecast 2021-2026 Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.9 UK - Market size and forecast 2021-2026 Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.10 Canada - Market size and forecast 2021-2026 Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.11 China - Market size and forecast 2021-2026 Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 82: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 83: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 84: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 85: Overview on factors of disruption 9.4 Industry risks Exhibit 86: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 87: Vendors covered 10.2 Market positioning of vendors Exhibit 88: Matrix on vendor position and classification 10.3 Abbott Laboratories Exhibit 89: Abbott Laboratories - Overview Exhibit 90: Abbott Laboratories - Business segments Exhibit 91: Abbott Laboratories - Key news Exhibit 92: Abbott Laboratories - Key offerings Exhibit 93: Abbott Laboratories - Segment focus 10.4 Alfa Scientific Designs Inc Exhibit 94: Alfa Scientific Designs Inc - Overview Exhibit 95: Alfa Scientific Designs Inc - Product / Service Exhibit 96: Alfa Scientific Designs Inc - Key offerings 10.5 Ava AG Exhibit 97: Ava AG - Overview Exhibit 98: Ava AG - Key offerings 10.6 Church and Dwight Co. Inc. Exhibit 99: Church and Dwight Co. Inc. - Overview Exhibit 100: Church and Dwight Co. Inc. - Business segments Exhibit 101: Church and Dwight Co. Inc. - Key news Exhibit 102: Church and Dwight Co. Inc. - Key offerings Exhibit 103: Church and Dwight Co. Inc. - Segment focus 10.7 Geratherm Medical AG Exhibit 104: Geratherm Medical AG - Overview Exhibit 105: Geratherm Medical AG - Business segments Exhibit 106: Geratherm Medical AG - Key offerings Exhibit 107: Geratherm Medical AG - Segment focus 10.8 Quanovate Tech Inc. Exhibit 108: Quanovate Tech Inc. - Overview Exhibit 109: Quanovate Tech Inc. - Key offerings 10.9 Quidel Corp. Exhibit 110: Quidel Corp. - Overview Exhibit 111: Quidel Corp. - Product / Service Exhibit 112: Quidel Corp. - Key offerings 10.10 The Procter and Gamble Co. Exhibit 113: The Procter and Gamble Co. - Overview Exhibit 114: The Procter and Gamble Co. - Product / Service Exhibit 115: The Procter and Gamble Co. - Key news Exhibit 116: The Procter and Gamble Co. - Key offerings 10.11 UEBE Medical GmbH Exhibit 117: UEBE Medical GmbH - Overview Exhibit 118: UEBE Medical GmbH - Product / Service Exhibit 119: UEBE Medical GmbH - Key offerings 10.12 Valley Electronics AG Exhibit 120: Valley Electronics AG - Overview Exhibit 121: Valley Electronics AG - Product / Service Exhibit 122: Valley Electronics AG - Key offerings 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 123: Inclusions checklist Exhibit 124: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 125: Currency conversion rates for US$ 11.4 Research methodology Exhibit 126: Research methodology Exhibit 127: Validation techniques employed for market sizing Exhibit 128: Information sources 11.5 List of abbreviations Exhibit 129: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email:[email protected] Website: SOURCE Technavio

100 Deals associated with Church & Dwight Co., Inc.

100 Translational Medicine associated with Church & Dwight Co., Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 29 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Potassium bicarbonate	Osteoporosis More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis